Association Between Genomic Recurrence Risk and Well-Being Among Breast Cancer Patients

PUBLICATION: BMC Cancer. 2013 Jun 18;13:295. doi: 10.1186/1471-2407-13-295. AUTHORS: Retรจl Read More

2024-03-25T10:45:47-04:00June 18th, 2013|Adjuvant, Evidence, MammaPrint, MINDACT, Other|

Molecular Subtyping of Early-Stage Breast Cancer Identifies a Group of Patients Who Do Not Benefit from Neoadjuvant Chemotherapy

PUBLICATION:ย  Breast Cancer Res Treat. 2013 Jun;139(3):759-67. doi: 10.1007/s10549-013-2572-4. AUTHORS:ย  Read More

2024-03-25T10:46:58-04:00June 12th, 2013|BluePrint, Evidence, Neoadjuvant|

Multigene Assays and Molecular Markers in Breast Cancer: Systematic Review of Health Economic Analyses

PUBLICATION: Breast Cancer Res Treat. 2013 Jun;139(3):621-37. doi: 10.1007/s10549-013-2559-1. Epub Read More

2024-03-25T10:47:25-04:00June 1st, 2013|Evidence, Healthcare Economics, MammaPrint, Other|

A Prospective Evaluation of a Breast Cancer Prognosis Signature in the Observational RASTER Study

PUBLICATION: Int J Cancer. 2013 Aug 15;133(4):929-36. doi: 10.1002/ijc.28082. Epub Read More

2024-03-25T10:47:48-04:00January 13th, 2013|Adjuvant, Evidence, MammaPrint, RASTER|

Additional Value of the 70-gene Signature and Levels of ER and PR for the Prediction of Outcome in Tamoxifen-Treated, ER-Positive Breast Cancer

PUBLICATION: The Breast. 2012 Dec;21(6):769-78. doi: 10.1016/j.breast.2012.04.010. Epub 2012 Jun Read More

2024-03-25T10:49:46-04:00December 1st, 2012|Endocrine, Evidence, MammaPrint|

Lobular Histology and Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer

PUBLICATION: Breast Cancer Res Treat. 2012 Nov;136(1):35-43. doi: 10.1007/s10549-012-2233-z. Epub Read More

2024-03-25T10:51:13-04:00November 1st, 2012|Evidence, Lobular, MammaPrint, Neoadjuvant, Other|

Comparison of Molecular Subtyping with BluePrint, MammaPrint, and TargetPrint to Local Clinical Subtyping in Breast Cancer Patients

PUBLICATION: Ann Surg Oncol. 2012 Oct;19(10):3257-63. doi: 10.1245/s10434-012-2561-6. Epub 2012 Read More

2024-03-25T10:51:59-04:00August 15th, 2012|BluePrint, Evidence, Other, Validation|

Economic Evaluation of the 70-gene Prognosis-Signature (MammaPrintยฎ) in Hormone Receptor-Positive, Lymph Node-Negative, Human Epidermal Growth Factor Receptor Type 2-Negative Early Stage Breast Cancer in Japan

PUBLICATION: Breast Cancer Res Treat. 2012 Jun;133(2):759-68. doi: 10.1007/s10549-012-1979-7. AUTHORS: Read More

2024-03-25T10:52:27-04:00June 1st, 2012|Evidence, Healthcare Economics, MammaPrint, Other|

A Diagnostic Gene Profile for Molecular Subtyping of Breast Cancer Associated with Treatment Response

PUBLICATION: Breast Cancer Res Treat (2012) 133: 37. https://doi.org/10.1007/s10549-011-1683-z. AUTHORS: Read More

2024-03-25T10:54:08-04:00May 1st, 2012|BluePrint, Evidence, Neoadjuvant|
Go to Top